Patents Issued in June 27, 2019
  • TRANSDERMAL FORMULATIONS
    Publication number: 20190192663
    Abstract: The present disclosure is directed to transdermal and moisturizing compositions.
    Type: Application
    Filed: March 5, 2019
    Publication date: June 27, 2019
    Inventor: Steven Hoffman
  • COLLOIDAL PARTICLES FOR USE IN MEDICINE
    Publication number: 20190192664
    Abstract: The invention provides a composition comprising a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer for use in medicine, wherein said composition does not contain any pharmaceutically active agent.
    Type: Application
    Filed: October 14, 2016
    Publication date: June 27, 2019
    Inventors: William HENRY, Richard WOLF-GARRAWAY, John Charles MAYO
  • BIODEGRADABLE DRUG DELIVERY COMPOSITIONS
    Publication number: 20190192665
    Abstract: A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed.
    Type: Application
    Filed: September 21, 2018
    Publication date: June 27, 2019
    Applicant: MEDINCELL
    Inventor: Georges GAUDRIAULT
  • COMPOSITIONS AND METHODS FOR DELIVERING AN AGENT TO A WOUND
    Publication number: 20190192666
    Abstract: The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).
    Type: Application
    Filed: July 31, 2018
    Publication date: June 27, 2019
    Applicant: UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION
    Inventors: WARREN O. HAGGARD, SCOTT P. NOEL, JOEL D. BUMGARDNER
  • HEMOSTATIC MICROSPHERES
    Publication number: 20190192667
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 27, 2019
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20190192668
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 27, 2019
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang
  • TLR9 TARGETED THERAPEUTICS
    Publication number: 20190192669
    Abstract: Disclosed are compositions and methods for targeted treatment of cancers, such as TLR9-expressing cancers. In particular, molecules containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, that target lytic peptides to TLR9-expressing malignant cells are disclosed.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 27, 2019
    Inventors: Alan List, Sheng Wei
  • BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF
    Publication number: 20190192670
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-?-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: March 1, 2019
    Publication date: June 27, 2019
    Inventors: Travis Mickle, Sven Guenther, Guochen Chi, Jaroslaw Kanski, Andrea K Martin, Bindu Bera
  • POLYMER, METHOD FOR PRODUCING POLYMER, AND DRUG CONJUGATE
    Publication number: 20190192671
    Abstract: Provided is a polymer including a repeating unit (I) represented by Formula (I) and a repeating unit (II) represented by Formula (II) (in the formulae, m represents 1 or 2, L represents a divalent aromatic hydrocarbon group or a divalent aliphatic hydrocarbon group, R1 represents a hydrogen atom, an aliphatic hydrocarbon group, or an aromatic hydrocarbon group, X represents ORx, SRx, or NRx1Rx2, Rx represents a hydrogen atom, an aliphatic hydrocarbon group, or an aromatic hydrocarbon group, Rx1 and Rx2 each independently represent a hydrogen atom, an aliphatic hydrocarbon group, or an aromatic hydrocarbon group).
    Type: Application
    Filed: August 23, 2017
    Publication date: June 27, 2019
    Inventors: Sabina Quader, Horacio Cabral, Hiroaki Kinoh, Kazunori Kataoka
  • DRUG DELIVERY POLYMER AND USES THEREOF
    Publication number: 20190192672
    Abstract: Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as cisplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 27, 2019
    Applicant: Massachusetts Institute of Technology
    Inventors: Jeremiah A. Johnson, Longyan Liao
  • PEGYLATED PORCINE INTERFERON AND METHODS OF USE THEREOF
    Publication number: 20190192673
    Abstract: Disclosed herein are porcine interferon alpha variants (pINF-?) comprising a synthetic amino acid at select locations in pINF-? and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pINF-? variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.
    Type: Application
    Filed: June 16, 2017
    Publication date: June 27, 2019
    Inventors: Peter Connor CANNING, Nickolas KNUDSEN, Lillian SKIDMORE
  • NUCLEIC ACID CONJUGATE
    Publication number: 20190192674
    Abstract: The present invention provides a nucleic acid conjugate in which a sugar chain ligand is bonded to an oligonucleotide via a linker, the sugar chain ligand having O-bonded mannose at its non-reducing end.
    Type: Application
    Filed: June 30, 2017
    Publication date: June 27, 2019
    Applicant: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Keiji UEHARA, Yasuhiro SUZUKI, Toshimasa HARUMOTO, Hiroto IWAI, Asana MAKINO
  • INSULIN DIMER-INCRETIN CONJUGATES
    Publication number: 20190192675
    Abstract: Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.
    Type: Application
    Filed: April 21, 2017
    Publication date: June 27, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan PALANI, ZhiQiang YANG, Lin YAN, Songnian LIN, Pei HUO, Ravi NARGUND
  • IMMUNOSTIMULANT
    Publication number: 20190192676
    Abstract: A complex comprising a carrier containing a plasma-derived protein or serum-derived protein solidified by denaturation coagulation, and a protein having a peroxidase-like activity and carried by the carrier, which has such high effectiveness that it can strongly stimulate an antigen-presenting cell, and can be used as a highly safe immunostimulant with reduced toxicity to living bodies.
    Type: Application
    Filed: September 5, 2017
    Publication date: June 27, 2019
    Applicant: CELL- MEDICINE, INC.
    Inventor: Tadao OHNO
  • CONJUGATE OF MINOXIDIL AND PEPTIDE
    Publication number: 20190192677
    Abstract: The present invention relates to a composition for preventing hair loss and, more specifically, to a compound having a structure in which Minoxidil and a peptide are chemically connected, and to a pharmaceutical composition or cosmetic composition for preventing hair loss or promoting hair growth comprising the compound. The compound having a structure in which Minoxidil and a peptide are chemically connected according to the present invention has not only excellent physiological activity such as hair loss reduction, hair growth promotion or cell growth promotion, but also excellent stability in water, and can therefore be useful as a composition for preventing hair loss and promoting hair growth.
    Type: Application
    Filed: August 4, 2017
    Publication date: June 27, 2019
    Applicant: CAREGEN CO., LTD.
    Inventors: Yong Ji CHUNG, Eun Mi KIM
  • SYSTEM AND METHOD FOR THE TREATMENT OF DISEASE USING A HYPERSPECIFIC MODIFIED PROTEIN SYSTEM
    Publication number: 20190192678
    Abstract: A hyperspecific MP system is a system of at least 3 different types of Modified Proteins expressed on/in any cell type and operating together in a treatment, diagnostic, commercial method, or other commercial method(s). Using multiple Modified Proteins can significantly increase the specificity of cancer treatment among many others and decrease side effects of treatments.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 27, 2019
    Inventor: Jayanth Venkata Nagendra S Batchu
  • Nanocarriers for Intracellular Delivery
    Publication number: 20190192679
    Abstract: An embodiment of the present disclosure can include a nanocarrier for delivering a cargo to a cell comprising: a bundle domain and a binding domain, the binding domain configured to bind to the cargo. An embodiment of the present disclosure can include a method for delivering a cargo to a cell comprising: introducing an amino-acid based nanocarrier to the cell, the nanocarrier can comprise an alpha-helical protein bundle domain and a binding domain, the cargo can bound to the binding domain and the cargo can be therapeutic cargo.
    Type: Application
    Filed: June 7, 2017
    Publication date: June 27, 2019
    Inventors: Julie Champion, Sung In Lim
  • Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate
    Publication number: 20190192680
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-substituted heteroaryl compounds used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates and compounds, as well as methods of using the same.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 27, 2019
    Inventors: Stepan Chuprakov, Romas Alvydas Kudirka, Jesse M. McFarland, Albert W. Garafalo, David Rabuka
  • NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
    Publication number: 20190192681
    Abstract: Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.
    Type: Application
    Filed: October 4, 2018
    Publication date: June 27, 2019
    Inventors: Andrew John GEALL, Venkata Ramana DOPPALAPUDI, Joel Daniel ARIAS, David Sai-Ho CHU, Michael Caramian COCHRAN, Rob BURKE, Philip KOVACH, Barbora MALECOVA
  • COMPOSITIONS AND METHODS FOR THE DEPLETION OF CELLS
    Publication number: 20190192682
    Abstract: The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Inventors: Andrew Nixon, Dwight Morrow, Adam Hartigan
  • CNS-TARGETED CONJUGATES HAVING MODIFIED FC REGIONS AND METHODS OF USE THEREOF
    Publication number: 20190192683
    Abstract: Provided are central nervous system (CNS)-targeted antibody or therapeutic Fc-fusion polypeptide conjugates having modified Fc regions, and related methods of use thereof, for instance, to facilitate delivery of therapeutic and/or diagnostic polypeptides across the blood-brain barrier (BBB), and thereby treat and/or diagnose conditions associated with the CNS, including cancer, pain, and various neuropathologies, such as neuroinflammatory, auto-immune, and/or neurodegenerative disorders.
    Type: Application
    Filed: December 22, 2017
    Publication date: June 27, 2019
    Inventor: Wilfred Arthur JEFFERIES
  • INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID
    Publication number: 20190192684
    Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 27, 2019
    Inventors: James D. PIPKIN, Rupert O, ZIMMERER, Diane O. THOMPSON, Gerold L. MOSHER
  • A DELTA-OPIOID RECEPTOR TARGETED AGENT FOR MOLECULAR IMAGING AND IMMUNOTHERAPY OF CANCER
    Publication number: 20190192685
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.
    Type: Application
    Filed: May 4, 2017
    Publication date: June 27, 2019
    Inventors: Mark L. McLaughlin, David L. Morse
  • TARGETED NANODROPLET EMULSIONS FOR TREATING CANCER
    Publication number: 20190192686
    Abstract: A micelle, comprises a first phospholipid, a second phospholipid, a targeting agent, conjugated to the first phospholipid, a perfluorocarbon, and a therapeutically active compound. The first phospholipid and the second phospholipid form a shell enclosing the perfluorocarbon and the therapeutically active compound. The targeting agent comprises an anti-nucleolin agent, and the therapeutically active compound comprises a chemotherapeutic agent and/or a cytotoxic agent. An emulsion may be formed, comprising a plurality of the micelles, and continuous aqueous phase. A pharmaceutical composition for treating cancer may be prepared, comprising the emulsion, and a pharmaceutically acceptable carrier. A method of treating cancer includes administering an effective amount of the pharmaceutical composition to a patient in need thereof.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 27, 2019
    Inventors: Mohammad Tariq Malik, Jonathan A. Kopechek, Paula J. Bates
  • RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF
    Publication number: 20190192687
    Abstract: The invention discloses the use of single-stranded RNA toeholds of different lengths to promote the re-association of various RNA-DNA hybrids, which results in activation of multiple split functionalities inside human cells. Previously designed RNA/DNA nanoparticles employed single-stranded DNA toeholds to initiate re-association. The use of RNA toeholds is advantageous because of the simpler design rules, the shorter toeholds, and the smaller size of the resulting nanoparticles compared to the same hybrid nanoparticles with single-stranded DNA toeholds. Moreover, the co-transcriptional assemblies result in higher yields for hybrid nanoparticles with ssRNA toeholds.
    Type: Application
    Filed: February 13, 2017
    Publication date: June 27, 2019
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Service
    Inventors: Bruce Allen Shapiro, Kirill Andreevich Afonin, Mathias D. Viard, Eckart H.U. Bindewald, Lorena Parlea
  • Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency
    Publication number: 20190192688
    Abstract: The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Kim Askew, Jou-Ku Chung, Frank DeRosa, Michael Heartlein, Shrirang Karve, Thomas McCauley, Lianne Smith, Ann J. Barbier
  • LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY
    Publication number: 20190192689
    Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 27, 2019
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • LIVER SPECIFIC DELIVERY OF MESSENGER RNA
    Publication number: 20190192690
    Abstract: Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids. The compositions disclosed herein demonstrate a high transfection efficacy and are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 27, 2019
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • REGULATED BIOCIRCUIT SYSTEMS
    Publication number: 20190192691
    Abstract: The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
    Type: Application
    Filed: April 11, 2017
    Publication date: June 27, 2019
    Inventors: Peter Barrett, Michael N. Gladstone, Tariq A. Kassum, Vipin Suri, Dan Jun Li, Dexue Sun, Brian Dolinski
  • DNA Monoclonal Antibodies Targeting IL-6 and CD126
    Publication number: 20190192692
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-IL-6 and/or anti-CD 126 synthetic antibody. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Application
    Filed: May 5, 2017
    Publication date: June 27, 2019
    Inventors: David B. Weiner, Sarah Elliott
  • METHODS AND VECTORS FOR TREATING CNS DISORDERS
    Publication number: 20190192693
    Abstract: Methods and uses of treating a disease in a mammal are provided by administering to a mammalian non-central nervous system (CNS) cell, organ or tissue, for delivery to mammalian CNS (e.g., brain). Methods and uses of treating a disease in a mammal include, inter alia, administering to a mammalian non-ocular cell, organ or tissue for delivery to a mammalian ocular cell, organ or tissue.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 27, 2019
    Applicants: Spark Therapeutics, Inc., The Children's Hospital of Philadelphia
    Inventors: Katherine A. HIGH, Beverly L. DAVIDSON
  • COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE
    Publication number: 20190192694
    Abstract: The present disclosure relates to compositions and methods for assessing blood vessels and organs of the body, more specifically to methods for assessing the vasculature of the eye.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Inventors: Richard B. Dorshow, Thomas E. Rogers
  • PROCESS FOR USING OPTICAL AGENTS
    Publication number: 20190192695
    Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Inventors: Richard B. Dorshow, Raghavan Rajagopalan, Dennis A. Moore, Scott T. Depierro
  • METHODS OF USING OPTICAL AGENTS
    Publication number: 20190192696
    Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Inventors: Richard B. Dorshow, Raghavan Rajagopalan, Dennis A. Moore, Scott T. Depierro
  • CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF
    Publication number: 20190192697
    Abstract: Described herein are probe compounds that interact with the LOXL2 receptor, methods of making such probe compounds, and methods of using such probe compounds in vitro and in vivo.
    Type: Application
    Filed: September 6, 2017
    Publication date: June 27, 2019
    Inventors: Martin W. ROWBOTTOM, John Howard HUTCHINSON, Jillian Frances EVANS, Gretchen BAIN
  • A METHOD FOR OBTAINING INDICATOR SIGNALS FROM A CELL
    Publication number: 20190192698
    Abstract: The present invention relates to a field of genetically edited cells and furthermore determining indicator signals of genetically edited cells. The invention relates to a method for obtaining indicator signals from a cell, and more particularly to a method for determining a biological state of a cell. Furthermore, the present invention relates to a regenerative cell and use of a regenerative cell or a specific indicator poly-nucleotide for monitoring purposes. Also, a system for carrying out the method of the present invention is included.
    Type: Application
    Filed: December 22, 2016
    Publication date: June 27, 2019
    Inventors: Eero PUNKKA, Seppo VAINIO
  • NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF
    Publication number: 20190192699
    Abstract: Highly potent and selective radionuclide-based imaging and therapy agents targeting carbonic anhydrase IX with minimum non-specific organ uptake are disclosed. Methods of imaging and/or treating carbonic anhydrase IX-expressing cells or tumors also are disclosed.
    Type: Application
    Filed: May 12, 2017
    Publication date: June 27, 2019
    Inventors: Xing YANG, Il MINN, Steven ROWE, Sangeeta RAY, Ronnie C. MEASE, Michael GORIN, Mohamad ALLAF, Martin G. POMPER
  • ANTICANCER THERAPY
    Publication number: 20190192700
    Abstract: A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.
    Type: Application
    Filed: November 6, 2018
    Publication date: June 27, 2019
    Inventor: Jeffrey P. Norenberg
  • METHOD FOR TUMOR-TARGETING TREATMENT AND DIAGNOSIS, CONJUGATES USED FOR THE SAME, AND PREPARATION METHOD THEREOF
    Publication number: 20190192701
    Abstract: Provided are a conjugate including an EGFR inhibitor that enables treatment and diagnosis of epidermal growth factor receptor (EGFR)-overexpressing tumors including resistant tumors, a method that enables drug delivery treatment and diagnosis of EGFR-overexpressing tumors using the conjugate, and a method of preparing the conjugate.
    Type: Application
    Filed: December 26, 2018
    Publication date: June 27, 2019
    Applicant: Korea Institute of Radiological & Medical Sciences
    Inventors: Tae Sup Lee, Ik Joon Choi, Joo Hyun Kang
  • STABILIZED RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN COMPOSITIONS
    Publication number: 20190192702
    Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.
    Type: Application
    Filed: March 11, 2019
    Publication date: June 27, 2019
    Applicant: Actinium Pharmaceuticals, Inc.
    Inventors: Kaushik J. Dave, Shubh D. Sharma
  • TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXETAN
    Publication number: 20190192703
    Abstract: The disclosure relates to the use of 177Lu-lilotomab satetraxetan in the treatment of Non-Hodgkin lymphoma. Aspects included are specific administration patterns, with specific concentrations, pre-treatments and predosing.
    Type: Application
    Filed: September 15, 2017
    Publication date: June 27, 2019
    Inventors: Jostein Dahle, Simon Turner
  • INACTIVATION OF PATHOGENS IN BIOLOGICAL MEDIA
    Publication number: 20190192704
    Abstract: The invention relates to the processing of fluid biological media, especially of culture media or cell- or virus suspensions, potentially containing active pathogens, with the aim of inactivating these pathogens and/or modifying ingredients in these biological media by thermal or radiological treatment.
    Type: Application
    Filed: August 31, 2017
    Publication date: June 27, 2019
    Applicant: FRAUNHOFER-GESELLSCHAFT ZUR FÖDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Martin THOMA, Klaus FISCHER, Javier PORTILLO
  • ULTRAVIOLET SANITATIONS SYSTEM AND METHOD
    Publication number: 20190192705
    Abstract: A ultraviolet sanitation system including a towel assembly, a body configured to be an upward facing hollow-half-sphere and to contain a sanitizing liquid, a plate including two grooves, each of the grooves configured to accept a t-handle and a roller-ball of the towel assembly with the plate affixable to the body, and a plurality of wringing-rollers within the body beneath the plate configured to remove excess moisture from the towel assembly during use. Also include is an arm-assembly affixable to the base configured to restrain the plate, a sanitizing ultraviolet-light-source contained with the body below the plate, a base affixable to a bottom of the body, and a power-source electrically coupled to said ultraviolet-light-source.
    Type: Application
    Filed: October 2, 2017
    Publication date: June 27, 2019
    Inventor: MITCHELL JAMES MASYK
  • Disinfecting Methods and Apparatus
    Publication number: 20190192706
    Abstract: Light disinfecting systems are provided in which light emanating from an end or side of an optical fiber is used to disinfect a target site. According to one implementation a light beam emanating from an end emitting optical fiber is directed into a body that includes a plurality of optical surfaces that are configured to direct at least a portion of the beam of bacterial disinfecting light to the target site. According to one implementation the plurality of optical surfaces include a first refractive optical surface, a second refractive optical surface and a total reflective surface with the total reflective optical surface being disposed between the first and second refractive optical surfaces in a designated optical pathway of the beam of bacterial disinfecting light.
    Type: Application
    Filed: December 22, 2017
    Publication date: June 27, 2019
    Inventor: Brett M. ZABORSKY
  • Disinfecting Methods and Apparatus
    Publication number: 20190192707
    Abstract: Light disinfecting systems are provided in which light emanating from an end or side of an optical fiber is used to disinfect a target site. According to one implementation a light beam emanating from an end emitting optical fiber is directed into a body that includes a plurality of optical surfaces that are configured to direct at least a portion of the beam of bacterial disinfecting light to the target site. According to one implementation the plurality of optical surfaces include a first refractive optical surface, a second refractive optical surface and a total reflective surface with the total reflective optical surface being disposed between the first and second refractive optical surfaces in a designated optical pathway of the beam of bacterial disinfecting light.
    Type: Application
    Filed: December 22, 2017
    Publication date: June 27, 2019
    Inventor: Brett M. ZABORSKY
  • MICROBE INACTIVATION PROCESSING DEVICE AND CELL ACTIVATION PROCESSING DEVICE
    Publication number: 20190192708
    Abstract: Disclosed are a microbe inactivation processing device that can perform inactivation processing of microbes, while damage to human body cells is prevented or inhibited, with an efficient use of light emitted from a light source and the obtainment of a large effective irradiation area. Also provided are a cell activation processing device that can reliably activate target cells with high efficiency. The microbe inactivation processing device includes: a light source configured to emit light having a wavelength within a wavelength range of 190 nm to 237 nm; a power supply unit configured to supply electric power to the light source; a control unit configured to control the power supply unit; and an optical filter. The microbe inactivation processing device is configured to perform inactivation processing of a target microbe by applying the light emitted from the light source through the optical filter.
    Type: Application
    Filed: December 26, 2018
    Publication date: June 27, 2019
    Applicant: Ushio Denki Kabushiki Kaisha
    Inventor: Tatsushi IGARASHI
  • MICROBE INACTIVATION PROCESSING METHOD AND CELL ACTIVATION PROCESSING METHOD
    Publication number: 20190192709
    Abstract: Disclosed are a microbe inactivation processing method that can perform inactivation processing of microbes, while damage to human body cells is prevented or inhibited, with an efficient use of light emitted from a light source and the obtainment of a large effective irradiation area. Also provided are a cell activation processing method that can reliably activate target cells with high efficiency. The microbe inactivation processing method includes: a step of applying light emitted from a light source through an optical filter, with the light source configured to emit light having a wavelength within a wavelength range of 190 nm to 237 nm, in order to perform inactivation processing of a target microbe.
    Type: Application
    Filed: December 26, 2018
    Publication date: June 27, 2019
    Applicant: Ushio Denki Kabushiki Kaisha
    Inventor: Tatsushi IGARASHI
  • A light control system and a method for exposing a sub-portion of a space with light within a predetermined spectral range at a predetermined threshold intensity
    Publication number: 20190192710
    Abstract: The present invention relates to a light control system. The light control system comprising: a plurality of light sources each configured to emit light within a predetermined spectral range, each of the plurality of light sources being configured to illuminate a corresponding sub-portion of a space, a sensor configured to within the space, detect a location of a human or an animal; and a control engine configured to control the plurality of light sources based on the detected location of the human or the animal such that a subportion of the space in which the human or the animal is not present is exposed to the light within the predetermined spectral range at a predetermined threshold intensity. A method for exposing a sub-portion of a space with light within a predetermined spectral range at a predetermined threshold intensity is also provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 27, 2019
    Inventors: Peter K ANDERSSON, Tord Wingren
  • PROCESS AND APPARATUS FOR CLEANING, DISINFECTION, STERILIZATION, OR COMBINATIONS THEREOF
    Publication number: 20190192711
    Abstract: Apparatus and methods are provided for cleaning, disinfecting, and/or sterilizing a device. More specifically, a first treatment chamber can be configured to conduct a first treatment stage therein at a first pressure, a first temperature, and a first sterilant concentration. A first passage can be operatively connected to the first treatment chamber and a second treatment chamber can be operatively connected to the first passage and in communication with the first chamber via the first passage. The second chamber can be configured to conduct a second treatment stage therein at a second pressure, a second temperature, and a second sterilant concentration. An object can be treated in the first treatment chamber and moved to the second treatment chamber via the first passage to be treated in the second treatment chamber.
    Type: Application
    Filed: December 26, 2017
    Publication date: June 27, 2019
    Inventor: Morris Fuller Fox, III
  • STORAGE APPARATUS AND METHOD FOR IDENTIFYING A POSITION OF AN OBJECT
    Publication number: 20190192712
    Abstract: An apparatus and method are disclosed for identifying the position of an object that is, or will be, used in a sterilization process. The apparatus comprises at least two containers and each container has a cavity configured to receive the object. At least one visual indicator corresponds to each container. A programmable hardware device is configured to receive an identifier. Responsive to receipt of the identifier, the programmable hardware device is configured to indicate a position of at least one of the containers that corresponds to the identifier utilizing the visual indicator.
    Type: Application
    Filed: December 26, 2017
    Publication date: June 27, 2019
    Inventors: Yan Fang, Nick N. Nguyen, Mohammad Khair